Form 4: 60 Degrees Pharmaceuticals Director Settles Restricted Stock Units
SEC Form 4
Director Charles Allen settles restricted stock units for common stock in 60 Degrees Pharmaceuticals.
Summary
- On May 16, 2024, Charles Allen, a director of 60 Degrees Pharmaceuticals, settled 4,000 restricted stock units (RSUs) for shares of common stock.
- The transaction was executed at a price of $0.223 per share.
- Following the transaction, Allen directly owns 14,000 shares of common stock.
- Allen previously held 8,000 RSUs granted on July 11, 2023, which were modified to 4,000 RSUs fully vested as of December 31, 2023.
- After the settlement, Allen no longer owns any RSUs.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding the settlement of restricted stock units, indicating a neutral sentiment.
Industry Context
This is a standard disclosure related to insider transactions and is common for publicly traded companies.
Stakeholder Impact
- The settlement of RSUs may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/11/2023 | Charles Allen was initially granted 8,000 restricted stock units. |
| 12/31/2023 | The restricted stock units were modified to 4,000 RSUs, fully vested. |
| 05/16/2024 | 4,000 restricted stock units were settled for common stock. |
| 05/21/2024 | Date of the Form 4 filing. |
Keywords
Form 4, Director, Charles Allen, Restricted Stock Units, SXTP, 60 Degrees Pharmaceuticals, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.